CONNECT WITH US
HealthTech

HealthTech

nPhase Raises $30M to Scale AI-Native Clinical Data Fabrics and Agentic Workflows for Life Sciences

HIT Consultant logo

Published on

Add as a preferred source on Google
nPhase Raises $30M to Scale AI-Native Clinical Data Fabrics and Agentic Workflows for Life Sciences

Clinical research data platform provider nPhase, Inc., announced the closing of a $30M Series D financing round led by Viking Global Investors .

The equity financing represents nPhase’s first institutional equity capital raise since 2017, underscoring nearly a decade of disciplined capital self-sufficiency and operational growth.

The capital injection will accelerate the global expansion of the enterprise nPhase.ai clinical data platform, which unifies a Unified Data Management System (UDMS) and a Statistical Computing Environment (SCE) across the drug development lifecycle.

The platform addresses a fundamental technological barrier facing federal initiatives such as ARPA-H’s SURPASS program under HHS’s “Operation TrialBlazer,” which envisions continuous, adaptive clinical trials but contends with an industry constrained by fragmented, batch-processed data.

At the core of nPhase’s technology stack is nPhase.ai, an enterprise platform that unifies a Unified Data Management System (UDMS) with an advanced Statistical Computing Environment (SCE). By bridging electronic data capture (EDC)—including its widely utilized REDCap Cloud ecosystem for academic, nonprofit, and mid-market studies—with regulatory biostatistical analysis, the platform creates an unbroken, audited pipeline from patient encounter to electronic Common Technical Document (eCTD) submission:

Continuous Ingestion Across All Modalities: Aggregates raw trial data continuously from investigator sites, central laboratories, patient apps, and remote biosensors as it is generated, preventing the multi-month backlog typical of end-of-study data cleanups.

Stream-Based Harmonization: Replaces retrospective batch transformations by standardizing, cleansing, and validating clinical variables in near real time. Safety monitoring committees and clinical study directors can track adverse event clustering, signal detection, and protocol deviations instantaneously.

ai SCE, the system automatically translates raw, standardized clinical data into regulatory-ready analysis data models (CDISC ADaM) and formal statistical tables, figures, and listings (TFLs), compressing workflows that historically required four or more months down to a few weeks.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.